Granite Bio AG, a clinical-stage immunology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions, raises USD 100m in funding by completing a USD 30m Series A financing round led by founding investors Versant Ventures and Novartis Venture Fund, and a USD 70m Series B financing round led by Forbion, a leading global venture capital firm with offices in The Netherlands, Germany and USA, and Sanofi Ventures, the corporate venture capital arm of Sanofi, focused on investing in promising early-stage healthcare companies.

Granite Bio AG is pioneering a new approach to tackling inflammation, autoimmunity, and fibrosis by addressing fundamental disease drivers at their source. With the support of an exceptional investor syndicate and a world-class team, Granite Bio AG is advancing a pipeline of first-in-class therapies with the potential to transform patient outcomes.

VISCHER advised Forbion and Sanofi Ventures on all legal issues related to the transaction. The VISCHER team includes Christian Wyss (Partner, Corporate/M&A), Luzius Zumstein (Managing Associate, Corporate/M&A), Pauline Pfirter (Senior Associate, Corporate/M&A) and Alessandro L. Meyer (Associate, Corporate/M&A).

Author: Christian Wyss